Biointron Expands CRO Capabilities With Antibody Developability Assessment Platform

• Biointron has launched a comprehensive antibody developability assessment platform to support biologic drug discovery.

• The CRO platform is designed to identify manufacturability and stability risks early, helping reduce late-stage failures and development costs

Biointron announced the launch of its Antibody Developability Assessment platform, expanding its contract research organization (CRO) services to support early-stage biologic drug discovery. The platform is designed to help pharmaceutical and biotechnology companies identify potential manufacturing and stability risks before advancing candidates into later stages of development.

The service integrates high-throughput antibody expression with a broad panel of in vitro assays to evaluate key developability attributes, including stability, aggregation, binding performance, and physicochemical properties. According to the company, the platform enables rapid screening of antibody candidates and provides data-driven insights to support candidate selection.

Biointron indicated that early identification of developability risks is critical to reducing attrition rates in biologic drug development. By incorporating these assessments at the discovery stage, the CRO aims to help sponsors avoid costly delays and failures that often occur during later clinical or manufacturing phases.

The platform is designed for scalability, supporting high-throughput workflows capable of evaluating large numbers of antibody candidates within short timelines. This approach aligns with increasing industry demand for faster and more efficient biologics development as antibody pipelines expand across therapeutic areas.

“By identifying potential manufacturing challenges early in the discovery phase, our developability assessment platform enables more efficient candidate selection and helps reduce downstream risks in biologic drug development.”

Biointron Official Statement